Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
2024年9月11日 - 5:01AM
ビジネスワイヤ（英語）
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology
company focused on discovering and developing potential
best-in-class medicines for serious and rare diseases, today
announced that it has commenced an underwritten public offering of
$150 million of shares of its common stock and Series B non-voting
convertible preferred stock. All of the securities to be sold in
the underwritten public offering are being offered by Viridian. In
addition, Viridian intends to grant the underwriters a 30-day
option to purchase up to an additional $22.5 million of shares of
its common stock. Each share of Series B preferred stock will be
convertible into 66.67 shares of common stock at the election of
the holder, subject to beneficial ownership conversion limits
applicable to the Series B preferred stock.
Viridian intends to use the proceeds from the proposed
underwritten public offering of its shares of common stock and
Series B preferred stock, together with its cash, cash equivalents
and short-term investments, to further its clinical development
programs, as well as for working capital and general corporate
purposes.
Jefferies, Goldman Sachs & Co. LLC, Stifel and RBC Capital
Markets are acting as joint book-running managers for the offering.
Wedbush PacGrow is also acting as co-manager for this offering.
A registration statement relating to these securities has been
filed with the Securities and Exchange Commission (SEC) and became
effective on September 9, 2022. A preliminary prospectus supplement
and accompanying base prospectus relating to and describing the
terms of the offering will be filed with the SEC. The securities
described above have not been qualified under any state blue sky
laws. This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction. The offering will only be
made by means of a prospectus, copies of which may be obtained at
the SEC’s website at www.sec.gov, or by request to Jefferies LLC
(Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, New York, New York 10022; telephone: 877-821-7388; email:
Prospectus_Department@Jefferies.com); Goldman Sachs & Co. LLC
(Attention: Prospectus Department, 200 West Street, New York, NY
10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by
emailing Prospectus-ny@ny.email.gs.com); or Stifel, Nicolaus &
Company, Incorporated (Attention: Prospectus Department, One
Montgomery Street, Suite 3700, San Francisco, CA 94104, by
telephone at (415) 364-2720 or by email at
syndprospectus@stifel.com).
About Viridian Therapeutics, Inc.
Viridian is a biopharmaceutical company focused on engineering
and developing potential best-in-class medicines for patients with
serious and rare diseases. Viridian’s expertise in antibody
discovery and protein engineering enables the development of
differentiated therapeutic candidates for previously validated drug
targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the
treatment of patients with thyroid eye disease (TED). The company
is conducting a pivotal program for veligrotug, including two
global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate
its efficacy and safety in patients with active and chronic TED.
Viridian is also advancing VRDN-003 as a potential best-in-class
subcutaneous therapy for the treatment of TED, including two
ongoing global phase 3 clinical trials, REVEAL-1 and REVEAL-2, to
evaluate the efficacy and safety of VRDN-003 in patients with
active and chronic TED.
In addition to its TED franchise, Viridian is advancing a novel
portfolio of neonatal Fc receptor (FcRn) inhibitors, including
VRDN-006 and VRDN-008, which has the potential to be developed in
multiple autoimmune diseases.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements may be identified by the use of words such
as, but not limited to, “anticipate,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,” or
“would” or other similar terms or expressions that concern the
company’s expectations, plans and intentions. Forward-looking
statements include, without limitation, statements regarding the
proposed underwritten public offering; the company’s expectations
with respect to the use of the net proceeds from the proposed
underwritten public offering; the company’s belief that VRDN-003
may be a best-in-class subcutaneous therapy for the treatment of
TED; and the potential for the company’s novel portfolio of FcRn
inhibitors to be developed in multiple autoimmune diseases.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based on the
company’s current beliefs, expectations and assumptions. New risks
and uncertainties may emerge from time to time, and it is not
possible to predict all risks and uncertainties. No representations
or warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements. Such forward-looking
statements are subject to a number of material risks and
uncertainties including but not limited to: market conditions that
may affect the timing, terms or conditions of the proposed
underwritten public offering; the company’s successful completion
of the proposed underwritten public offering; the satisfaction of
customary closing conditions related to the proposed underwritten
public offering; and other risks and uncertainties identified in
the company’s filings with the SEC, including those risks set forth
under the caption “Risk Factors” in the company’s Quarterly Report
on Form 10-Q for the quarter ended June 30, 2024, filed with the
SEC on August 8, 2024, and other subsequent disclosure documents
filed with the SEC. Any forward-looking statement speaks only as of
the date on which it was made. Neither the company, nor its
affiliates, advisors or representatives, undertake any obligation
to publicly update or revise any forward-looking statement, whether
as a result of new information, future events or otherwise, except
as required by law. These forward-looking statements should not be
relied upon as representing the company’s views as of any date
subsequent to the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240910698560/en/
Investor & Media: Louisa Stone, 617-272-4604 Manager,
Investor Relations IR@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
過去 株価チャート
から 10 2024 まで 11 2024
Viridian Therapeutics (NASDAQ:VRDN)
過去 株価チャート
から 11 2023 まで 11 2024
